Cargando…

PM384. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616320/ http://dx.doi.org/10.1093/ijnp/pyw041.384

Ejemplares similares

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016)

PM516. Association of DNA Methylation of Taq1A in the DRD2 with Response to Aripiprazole in acute schizophrenia
por: Miura, Itaru, et al.
Publicado: (2016)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Clozapine-Treatment-Resistant Schizophrenia Successfully Managed with Brexpiprazole Combination Therapy: Two Case Reports
por: Orsolini, L., et al.
Publicado: (2022)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors
por: Hardy, Rachel E., et al.
Publicado: (2023)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

MIGRATION FROM OPC-DA TO OPC-UA
por: Farnham, B, et al.
Publicado: (2011)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples
por: Porcelli, Stefano, et al.
Publicado: (2016)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
por: Marpepa, B., et al.
Publicado: (2022)

Melting Points of OPC and OPC3 Water Models
por: Xiong, Yeyue, et al.
Publicado: (2020)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

ARIPIPRAZOLE-INDUCED OCULOGYRIC CRISIS (ACUTE DYSTONIA)
por: Rodriguez Andres, L., et al.
Publicado: (2023)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
por: Moleon, A., et al.
Publicado: (2023)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
por: Arai, Yusuke, et al.
Publicado: (2023)

PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia
por: Salzman, Phyllis, et al.
Publicado: (2016)

PM514. DRD2, 5-HT1A, and 5-HT2A gene polymorphisms and clinical factors modulate aripiprazole efficacy in different symptom dimensions of schizophrenia
por: Shen, Yu-Chih
Publicado: (2016)

PM439. Chronic effects of aripiprazole on the GSK3ß-dependent pathways, NMDA receptor and CREB1 in the rat brain
por: Pan, Bo, et al.
Publicado: (2016)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_71utk39ishle5stei6dsvuo1s7